Advanced gastric cancer: is chemotherapy needed after surgery?

Click to increase image sizeClick to decrease image size

Financial & competing interests disclosure

The authors have no relevant affiliations or financial involvements with any organization or entity that has a financial interest or conflict with the subject matter or materials discussed in this manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

No writing assistance was utilized in the production of this manuscript.

References

• Nakajima T, Nashimoto A, Kitamura M et al. Adjuvant mitomycin and fluorouracil followed by oral uracil plus tegafur in serosa-negative gastric cancer: a randomised trial. Gastric Cancer Surgical Study Group. Lancet 354(9175), 273–277 (1999).
   PubMedGoogle Scholar
• Sasako M, Sakuramoto S, Katai H et al. Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. J. Clin. Oncol. 29(33), 4387–4393 (2011).
   PubMed Web of Science ®Google Scholar
• Bang YJ, Kim YW, Yang HK et al. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. Lancet 379(9813), 315–321 (2012).
   PubMed Web of Science ®Google Scholar
• Japanese Gastric Cancer Association. Japanese Classification of Gastric Carcinoma – 2nd English Edition. Gastric Cancer 1(1), 10–24 (1998).
   Google Scholar
• American Joint Committee on Cancer. Cancer Staging Manual (6th Edition). Springer, IL, USA (2003).
   Google Scholar
• Ajani JA, Bentrem DJ, Besh S et al. Gastric cancer, version 2.2013: featured updates to the NCCN Guidelines. J. Natl Compr. Canc. Netk 11(5), 531–546 (2013).
   PubMed Web of Science ®Google Scholar
• Bonenkamp JJ, Hermans J, Sasako M et al. Extended lymph-node dissection for gastric cancer. N. Engl J. Med. 340(12), 908–914 (1999).
   PubMed Web of Science ®Google Scholar
• Songun I, Putter H, Kranenbarg EM, Sasako M, Van De Velde CJ. Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial. Lancet Oncol. 11(5), 439–449 (2010).
   PubMed Web of Science ®Google Scholar
• Allum WH, Blazeby JM, Griffin SM, Cunningham D, Jankowski JA, Wong R. Guidelines for the management of oesophageal and gastric cancer. Gut 60(11), 1449–1472 (2011).
   PubMed Web of Science ®Google Scholar
• Cunningham D, Allum WH, Stenning SP et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N. Engl J. Med. 355(1), 11–20 (2006).
   PubMed Web of Science ®Google Scholar
• Macdonald JS, Smalley SR, Benedetti J et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N. Engl J. Med. 345(10), 725–730 (2001).
   PubMed Web of Science ®Google Scholar
• Bickenbach K, Strong VE. Comparisons of gastric cancer treatments: East vs. West. J. Gastric Cancer 12(2), 55–62 (2012).
   PubMedGoogle Scholar
• Strong VE, Song KY, Park CH et al. Comparison of gastric cancer survival following R0 resection in the United States and Korea using an internationally validated nomogram. Ann. Surg. 251(4), 640–646 (2010).
   PubMed Web of Science ®Google Scholar
• Degiuli M, Sasako M, Ponti A, Calvo F. Survival results of a multicentre Phase II study to evaluate D2 gastrectomy for gastric cancer. Br. J. Cancer 90(9), 1727–1732 (2004).
   PubMed Web of Science ®Google Scholar
• Hoff PM, Saad ED, Ajani JA et al. Phase I study with pharmacokinetics of S-1 on an oral daily schedule for 28 days in patients with solid tumors. Clin. Cancer Res. 9(1), 134–142 (2003).
   PubMedGoogle Scholar
• Jeung HC, Rha SY, Shin SJ et al. Predictive values of 5-fluorouracil pathway genes for S-1 treatment in patients with advanced gastric cancer. Anti-cancer Drugs 22(8), 801–810 (2011).
   PubMedGoogle Scholar
• Simon RM, Paik S, Hayes DF. Use of archived specimens in evaluation of prognostic and predictive biomarkers. J. Natl Cancer Inst. 101(21), 1446–1452 (2009).
   PubMed Web of Science ®Google Scholar
• Karapetis CS, Khambata-Ford S, Jonker DJ et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N. Engl J. Med.359(17), 1757–1765 (2008).
   PubMed Web of Science ®Google Scholar
• Harris L, Fritsche H, Mennel R et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J. Clin. Oncol. 25(33), 5287–5312 (2007).
   PubMed Web of Science ®Google Scholar